How to buy iBio stock | $1.98

iBio, Inc is a biotechnology business based in the US. iBio shares (IBIO) are listed on the NYSE MKT and all prices are listed in US Dollars. iBio employs 43 staff and has a trailing 12-month revenue of around USD$1.9 million.

How to buy shares in iBio

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for iBio. Find the stock by name or ticker symbol: IBIO. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until iBio reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$1.98, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of iBio, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of iBio. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

iBio share price

Use our graph to track the performance of IBIO stocks over time.

iBio shares at a glance

• Key figures

Information last updated 2021-01-14.

Latest market close	USD$1.98
52-week range	USD$0.2302 - USD$7.45
50-day moving average	USD$1.2736
200-day moving average	USD$2.214
Wall St. target price	USD$2
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-0.943

Buy iBio shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy iBio stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of iBio, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

iBio price performance over time

Historical closes compared with the close of $1.98 from 2020-10-22

1 week (2021-01-08)	65.00%
1 month (2020-12-16)	80.00%
3 months (2020-10-16)	-3.41%
6 months (2020-07-16)	-39.26%

1 year (2020-01-16)	718.18%
2 years (2019-01-16)	120.00%
3 years (2018-01-16)	970.27%
5 years (2016-01-15)	253.57%

iBio financials

Revenue TTM	USD$1.9 million
Gross profit TTM	USD$1.6 million
Return on assets TTM	-14%
Return on equity TTM	-49.97%
Profit margin	0%
Book value	$0.444
Market capitalisation	USD$304.9 million

TTM: trailing 12 months

Shorting iBio shares

There are currently 12.0 million iBio shares held short by investors – that's known as iBio's "short interest". This figure is 12.5% down from 13.8 million last month.

There are a few different ways that this level of interest in shorting iBio shares can be evaluated.

iBio's "short interest ratio" (SIR)

iBio's "short interest ratio" (SIR) is the quantity of iBio shares currently shorted divided by the average quantity of iBio shares traded daily (recently around 13.1 million). iBio's SIR currently stands at 0.92. In other words for every 100,000 iBio shares traded daily on the market, roughly 920 shares are currently held short.

However iBio's short interest can also be evaluated against the total number of iBio shares, or, against the total number of tradable iBio shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case iBio's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 iBio shares in existence, roughly 60 shares are currently held short) or 0.057% of the tradable shares (for every 100,000 tradable iBio shares, roughly 57 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against iBio.

Find out more about how you can short iBio stock.

iBio share dividends

We're not expecting iBio to pay a dividend over the next 12 months.

Have iBio's shares ever split?

iBio's shares were split on a 1:10 basis on 11 June 2018. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your iBio shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for iBio shares which in turn could have impacted iBio's share price.

iBio share price volatility

Over the last 12 months, iBio's shares have ranged in value from as little as $0.2302 up to $7.45. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while iBio's is -5.8272. This would suggest that iBio's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, iBio has bucked the trend.

iBio overview

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and related conditions. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with AzarGen Biotechnologies (Pty) Ltd (AzarGen) for the contract development and manufacturing services for AzarGen's development of a rituximab biosimilar/biobetter for the South African market; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; collaboration with EdgePoint AI, a division of Mateon Therapeutics, Inc.; and collaboration agreement with CC-Pharming Ltd. iBio, Inc. is headquartered in New York, New York.

Frequently asked questions

• What percentage of iBio is owned by insiders or institutions?

  Currently 0.911% of iBio shares are held by insiders and 8.1% by institutions.

• How many people work for iBio?

  Latest data suggests 43 work at iBio.

• When does the fiscal year end for iBio?

  iBio's fiscal year ends in June.

• Where is iBio based?

  iBio's address is: 600 Madison Avenue, New York, NY, United States, 10022

• What is iBio's ISIN number?

  iBio's international securities identification number is: US4510332038

• What is iBio's CUSIP number?

  iBio's Committee on Uniform Securities Identification Procedures number is: 451033104